Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968862009> ?p ?o ?g. }
- W1968862009 endingPage "1023" @default.
- W1968862009 startingPage "1011" @default.
- W1968862009 abstract "Advanced glycation end product-modified proteins are known for accumulating during aging and in several pathological conditions such as diabetes, renal failure, and neurodegenerative disorders. There is little information about the intracellular fate of endocytosed advanced glycation end products (AGEs) and their influence on proteolytic systems. However, it is known that the lysosomal system is impaired during aging. Therefore, undegraded material may accumulate and play a considerable role in the development of diverse diseases. To investigate if AGEs can be degraded and to test whether they accumulate because of impaired lysosomal proteases we studied the effects of advanced glycation end products on the endosomal–lysosomal system. Five different types of AGEs were generated by bovine serum albumin incubation with glyoxal, methylglyoxal, glucose, fructose, and ribose. The first experiments revealed the uptake of AGEs by the macrophage cell line RAW 264.7. Further investigations demonstrated an increase in cathepsin D and L activity and an increase in mature cathepsins D and L. Increased activities were accompanied by the presence of more lysosomes, measured by staining with LysoTracker blue. To specify the roles of cathepsins D and L we used knockout cells to test the roles of both cathepsins on the toxicity of advanced glycation end products. In summary we conclude that both cathepsins are required for a reduction in advanced glycation end product-induced cytotoxicity." @default.
- W1968862009 created "2016-06-24" @default.
- W1968862009 creator A5003796136 @default.
- W1968862009 creator A5022568845 @default.
- W1968862009 creator A5025730250 @default.
- W1968862009 creator A5061376363 @default.
- W1968862009 creator A5080129565 @default.
- W1968862009 creator A5087695782 @default.
- W1968862009 date "2012-03-01" @default.
- W1968862009 modified "2023-10-12" @default.
- W1968862009 title "Cathepsins D and L reduce the toxicity of advanced glycation end products" @default.
- W1968862009 cites W127084926 @default.
- W1968862009 cites W1491202632 @default.
- W1968862009 cites W1517068612 @default.
- W1968862009 cites W1560487523 @default.
- W1968862009 cites W1562556996 @default.
- W1968862009 cites W1563369929 @default.
- W1968862009 cites W1572600466 @default.
- W1968862009 cites W1965706192 @default.
- W1968862009 cites W1966234811 @default.
- W1968862009 cites W1967111894 @default.
- W1968862009 cites W1971209988 @default.
- W1968862009 cites W1972304812 @default.
- W1968862009 cites W1977260572 @default.
- W1968862009 cites W1987876460 @default.
- W1968862009 cites W1991324547 @default.
- W1968862009 cites W1994519378 @default.
- W1968862009 cites W1995015428 @default.
- W1968862009 cites W1995443506 @default.
- W1968862009 cites W1997827566 @default.
- W1968862009 cites W2003733809 @default.
- W1968862009 cites W2004439008 @default.
- W1968862009 cites W2006193286 @default.
- W1968862009 cites W2008128102 @default.
- W1968862009 cites W2008387833 @default.
- W1968862009 cites W2011330952 @default.
- W1968862009 cites W2011886795 @default.
- W1968862009 cites W2012221118 @default.
- W1968862009 cites W2012731661 @default.
- W1968862009 cites W2016995602 @default.
- W1968862009 cites W2021230433 @default.
- W1968862009 cites W2034138847 @default.
- W1968862009 cites W2037541841 @default.
- W1968862009 cites W2039921716 @default.
- W1968862009 cites W2045551189 @default.
- W1968862009 cites W2051612655 @default.
- W1968862009 cites W2055385755 @default.
- W1968862009 cites W2055897605 @default.
- W1968862009 cites W2059193537 @default.
- W1968862009 cites W2069274491 @default.
- W1968862009 cites W2069588809 @default.
- W1968862009 cites W2071161163 @default.
- W1968862009 cites W2082113351 @default.
- W1968862009 cites W2087693731 @default.
- W1968862009 cites W2090553671 @default.
- W1968862009 cites W2095513500 @default.
- W1968862009 cites W2097631517 @default.
- W1968862009 cites W2107361477 @default.
- W1968862009 cites W2107488926 @default.
- W1968862009 cites W2109034822 @default.
- W1968862009 cites W2111999530 @default.
- W1968862009 cites W2114918609 @default.
- W1968862009 cites W2116033181 @default.
- W1968862009 cites W2118170059 @default.
- W1968862009 cites W2120833123 @default.
- W1968862009 cites W2125550664 @default.
- W1968862009 cites W2129182415 @default.
- W1968862009 cites W2132788189 @default.
- W1968862009 cites W2139369185 @default.
- W1968862009 cites W2142280970 @default.
- W1968862009 cites W2145439554 @default.
- W1968862009 cites W2147283347 @default.
- W1968862009 cites W2155982359 @default.
- W1968862009 cites W2157490824 @default.
- W1968862009 cites W2159842188 @default.
- W1968862009 cites W2166747071 @default.
- W1968862009 cites W4211069397 @default.
- W1968862009 cites W4231136244 @default.
- W1968862009 cites W4234505218 @default.
- W1968862009 cites W4247717176 @default.
- W1968862009 cites W4248311915 @default.
- W1968862009 doi "https://doi.org/10.1016/j.freeradbiomed.2011.12.021" @default.
- W1968862009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22245096" @default.
- W1968862009 hasPublicationYear "2012" @default.
- W1968862009 type Work @default.
- W1968862009 sameAs 1968862009 @default.
- W1968862009 citedByCount "47" @default.
- W1968862009 countsByYear W19688620092012 @default.
- W1968862009 countsByYear W19688620092013 @default.
- W1968862009 countsByYear W19688620092014 @default.
- W1968862009 countsByYear W19688620092015 @default.
- W1968862009 countsByYear W19688620092016 @default.
- W1968862009 countsByYear W19688620092017 @default.
- W1968862009 countsByYear W19688620092018 @default.
- W1968862009 countsByYear W19688620092019 @default.
- W1968862009 countsByYear W19688620092020 @default.
- W1968862009 countsByYear W19688620092021 @default.
- W1968862009 countsByYear W19688620092022 @default.